Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-24-085211
Filing Date
2024-10-04
Accepted
2024-10-04 08:30:30
Documents
4
Period of Report
2024-10-04

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0216708-6k_akanda.htm 6-K 11259
2 UNDERWRITING AGREEMENT DATED OCTOBER 2, 2024 ea021670801ex1-1_akanda.htm EX-1.1 212757
3 FORM OF PRE-FUNDED WARRANT ea021670801ex4-1_akanda.htm EX-4.1 94703
4 PRESS RELEASE DATED OCTOBER 4, 2024 ea021670801ex99-1_akanda.htm EX-99.1 9248
  Complete submission text file 0001213900-24-085211.txt   329042
Mailing Address 77 KING STREET WEST, SUITE 400 C/O DENTONS CANADA LLP TORONTO A6 M5K 0A1
Business Address 1A, 1B LEAROYD ROAD NEW ROMNEY X0 TN28 8XU 442034889514
AKANDA CORP. (Filer) CIK: 0001888014 (see all company filings)

EIN.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-41324 | Film No.: 241353609
SIC: 2833 Medicinal Chemicals & Botanical Products
(CF Office: 03 Life Sciences)